PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer

BJU International

Volumn 107, Issue 3, 2011, Pages 477-485

  Bismar, Tarek A ^a,g,h   Yoshimoto, Maisa ^b   Vollmer, Robin T ^c   Duan, Qiuli ^d   Firszt, Matthew ^e   Corcos, Jacques ^f   Squire, Jeremy A ^b  

^a CALGARY LABORATORY SERVICES   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c Tom Baker Cancer Center   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f TOM BAKER CANCER CENTRE   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

disease progression; ERG rearrangements; fluorescence in situ hybridization; Gleason score; high grade prostatic intra epithelial neoplasia; prostate cancer; PTEN

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; COPY NUMBER VARIATION; ERG GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE REARRANGEMENT; GLEASON SCORE; HEMIZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONOSOMY; PHOSPHOINOSITIDE 3 PHOSPHATASE GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

EID: 79251536870     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09470.x     Document Type: Article

References (47)

1. Demichelis F, Setlur SR, Beroukhim R, et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer 2009; 48: 366-80
2. Jalava SE, Porkka KP, Rauhala HE, Isotalo J, Tammela TL, Visakorpi T,. TCEB1 promotes invasion of prostate cancer cells. Int J Cancer 2009; 124: 95-102
3. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8
4. Jhavar S, Brewer D, Edwards S, et al. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int 2009; 103: 1256-69
5. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007; 67: 8504-10
6. Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008; 100: 815-25
7. Hyun T, Yam A, Pece S, et al. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 2000; 96: 3560-8
8. Facher EA, Law JC,. PTEN and prostate cancer. J Med Genet 1998; 35: 790
9. Wang SI, Parsons R, Ittmann M,. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998; 4: 811-5
10. Deocampo ND, Huang H, Tindall DJ,. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol 2003; 28: 145-53
11. Halvorsen OJ, Haukaas SA, Akslen LA,. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 2003; 9: 1474-9
12. Fenic I, Franke F, Failing K, Steger K, Woenckhaus J,. Expression of PTEN in malignant and non-malignant human prostate tissues: comparison with p27 protein expression. J Pathol 2004; 203: 559-66
13. Koksal IT, Dirice E, Yasar D, et al. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol 2004; 22: 307-12
14. Zhao H, Dupont J, Yakar S, Karas M, LeRoith D,. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 2004; 23: 786-94
15. El Sheikh SS, Romanska HM, Abel P, Domin J, Lalani el-N,. Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer-a pilot study. Neoplasia 2008; 10: 949-53
16. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41: 619-24
17. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10: 177-88
18. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448: 595-9
19. Squire JA,. TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet 2009; 41: 509-10
20. King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41: 524-6
21. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007; 97: 678-85
22. Sircar K, Yoshimoto M, Monzon FA, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009; 218: 505-13
23. Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008; 21: 1451-60
24. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008; 14: 3380-5
25. Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA,. TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a canadian cohort. Cancer Biol Ther 2009; 8: 125-30
26. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 2007; 31: 882-8
27. Yoshimoto M, Cutz JC, Nuin PA, et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006; 169: 128-37
28. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009; 22: 1083-93
29. Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128: 157-70
30. Darnel AD, Behmoaram E, Vollmer RT, et al. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res 2009; 15: 1376-83
31. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66: 8337-41
32. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT,. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007; 20: 921-8
33. Schmitz M, Grignard G, Margue C, et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007; 120: 1284-92
34. Sansal I, Sellers WR,. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-63
35. Shen MM, Abate-Shen C,. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res 2007; 67: 6535-8
36. Nami RK, Sugar L, Wang Z, et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007; 6: 40-5
37. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26: 4596-9
38. FitzGerald LM, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 2008; 8: 230
39. Hermans KG, Boormans JL, Gasi D, et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009; 15: 6398-403
40. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T,. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008; 14: 3395-400
41. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007; 60: 1238-43
42. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2007; 3: 253-63
43. Winnes M, Lissbrant E, Damber JE, Stenman G,. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007; 17: 1033-6
44. Wang J, Cai Y, Ren C, Ittmann M,. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006; 66: 8347-51
45. Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69: 2912-8
46. Sircar K, Yoshimoto M, Monzon FA, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009; 218: 505-13
47. McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J,. Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer 2008; 99: 1296-301